Jin Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin Ji has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bijiang Geng
School of Environmental and Chemical Engineering Shanghai University Shanghai China
1 shared publication Chen Kong
1 shared publicationChunmeng Wei
Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine Guangxi Medical University Nanning Guangxi China
1 shared publication- Fubo Wang
Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, University Engineering Research Center of Digital Medicine and Healthcare, Guangxi Medical University, Nanning, China
1 shared publication Huiyong Zhang
Center for Genomic and Personalized Medicine, Guangxi key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine Guangxi Medical University Nanning Guangxi China
1 shared publicationLin Zhao
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Elsevier in Asian Journal of Urology
- Vol. 13 (2) , 127-132
Navigating the tension between missed diagnosis and overdiagnosis: A comparison of the recent Chinese Urological Association and European Association of Urology guidelines on prostate biopsy
- 10 March 2026
- Published by Elsevier in Asian Journal of Urology
- Vol. 13 (2) , 127-132
Open AccessNavigating the tension between missed diagnosis and overdiagnosis: A comparison of the recent Chinese Urological Association and European Association of Urology guidelines on prostate biopsy
- 12 December 2022
- Published by Wiley in International Journal of Cancer
- Vol. 152 (8) , 1719-1727
Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles
The study aimed at evaluating the performance of urinary exosomal prostate‐specific antigen (UE‐PSA) to predict the results of initial prostate biopsies and discriminate clinically significant prostate cancer (Gleason score ≥ 7, csPCa) from nonsignificant PCa (Gleason score < 7, nsPCa) plus benign patients. Two hundred seventy‐two consecutive participants were admitted who underwent a prostate biopsy. The UE‐PSA expression was detected by enzyme‐linked immunosorbent assay (ELISA). The predictive power and clinical value of UE‐PSA was assessed by receiver operating characteristic (ROC), decision curve analysis (DCA) and waterfall plots. UE‐PSA was upregulated in PCa compared to benign patients (P < .001) and csPCa compared to nsPCa plus benign patients (P < .001). UE‐PSA achieved an AUC of 0.953 (0.905‐0.989) in distinguishing PCa from benign patients and an AUC of 0.879 (0.808‐0.941) in predicting csPCa from nsPCa plus benign patients. These results were validated in an additional multicenter cohort. In addition, DCA showed that UE‐PSA achieved the highest net benefit at almost any threshold probability compared to tPSA and %fPSA. As the waterfall plot showed, the UE‐PSA assay could avoid 57.6% (155 cases) and 34.6% (93 cases) unnecessary biopsies while only missing 2.6% (7 cases) and 1.5% (4 cases) of the cases of csPCa at the cutoff value of 90% and 95% sensitivity, respectively. We validated that UE‐PSA presented great diagnostic power and clinical utility to diagnose PCa and csPCa. UE‐PSA could be a promising noninvasive biomarker to improve PCa detection.
- 12 December 2022
- Published by Wiley in International Journal of Cancer
- Vol. 152 (8) , 1719-1727
Urinary exosomal prostate‐specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles
The study aimed at evaluating the performance of urinary exosomal prostate‐specific antigen (UE‐PSA) to predict the results of initial prostate biopsies and discriminate clinically significant prostate cancer (Gleason score ≥ 7, csPCa) from nonsignificant PCa (Gleason score < 7, nsPCa) plus benign patients. Two hundred seventy‐two consecutive participants were admitted who underwent a prostate biopsy. The UE‐PSA expression was detected by enzyme‐linked immunosorbent assay (ELISA). The predictive power and clinical value of UE‐PSA was assessed by receiver operating characteristic (ROC), decision curve analysis (DCA) and waterfall plots. UE‐PSA was upregulated in PCa compared to benign patients (P < .001) and csPCa compared to nsPCa plus benign patients (P < .001). UE‐PSA achieved an AUC of 0.953 (0.905‐0.989) in distinguishing PCa from benign patients and an AUC of 0.879 (0.808‐0.941) in predicting csPCa from nsPCa plus benign patients. These results were validated in an additional multicenter cohort. In addition, DCA showed that UE‐PSA achieved the highest net benefit at almost any threshold probability compared to tPSA and %fPSA. As the waterfall plot showed, the UE‐PSA assay could avoid 57.6% (155 cases) and 34.6% (93 cases) unnecessary biopsies while only missing 2.6% (7 cases) and 1.5% (4 cases) of the cases of csPCa at the cutoff value of 90% and 95% sensitivity, respectively. We validated that UE‐PSA presented great diagnostic power and clinical utility to diagnose PCa and csPCa. UE‐PSA could be a promising noninvasive biomarker to improve PCa detection.
- 5 May 2022
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (3) , 1-7
Analgesic Effect of Ropivacaine Pumped in the Sub Rectus Abdominis Muscle Sheath after Abdominoplasty
Background Abdominoplasty is a major surgical procedure in plastic surgery. It removes excess skin and fat, tightens abdominal muscles and fascia, restores normal abdominal anatomy and reshapes the distorted abdominal contour. According to the statistics released annually by International Society of Aesthetic Plastic Surgery (ISAPS) in 2020, there are more than 900, 000 abdominal wall plastic surgeries performed every year worldwide. However, the most commonly used analgesic methods, such as oral administration, intravenous analgesia and local infiltration anesthesia, do not provide the satisfactory analgesic results. We found that intra-sheath injection of ropivacaine of the rectus abdomen was effective in reducing postoperative pain. Objectives To retrospectively study the analgesic effect of continuous pumping ropivacaine into the intra-sheath space of rectus abdominis after abdominoplasty. Methods A retrospective study was conducted on 67 patients with total abdominal wall plastic surgery admitted to Plastic Surgery Hospital of Chinese Academy of Medical Sciences from February 2020 to August 2021. The patients were from 25 to 56 years old, with a mean age of 38.5, ASA grade 1–2, BMI 27–33kg/m2, and rectus abdominis muscle separation range of 4–8cm. Based on the methods of postoperative analgesia, we divided patients into the following two groups: 29 patients in the conventional intravenous analgesic group (group A) and 38 patients in the rectus abdominis intrathecal analgesic group (group B). Group A received PCA with sufentanil 1.0μg/kg+ normal saline diluted to 100ml. Group B received continuous pumping of ropivacaine (0.2625%) through the rectus sheath internal tube in 100mL of normal saline and continued pumping at a rate of 2mL /h. Visual analog pain score (VAS score), analgesic pump pressure times and the degree of postoperative satisfaction were recorded at T1 (24h) and T2 (48h). The incidence of adverse drug reactions and complications related to nerve block within one week after operation were also recorded. Results The clinical data of patients with total abdominal wall plastic surgery in two groups were collected and analyzed. The patients in group B overall had lower postoperative VAS score, less analgesic pump usage, less nausea, vomiting, drowsiness and restlessness and a higher degree of postoperative satisfaction than those in group A. Conclusion Continuous pumping of ropivacaine through rectus sheath can effectively relieve postoperative pain, reduce postoperative adverse reactions and improve postoperative satisfaction. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online instructions to Authors www.springer.com/00266. Body Contouring LOE IV
- 5 May 2022
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (3) , 1-7
Analgesic Effect of Ropivacaine Pumped in the Sub Rectus Abdominis Muscle Sheath after Abdominoplasty
Background Abdominoplasty is a major surgical procedure in plastic surgery. It removes excess skin and fat, tightens abdominal muscles and fascia, restores normal abdominal anatomy and reshapes the distorted abdominal contour. According to the statistics released annually by International Society of Aesthetic Plastic Surgery (ISAPS) in 2020, there are more than 900, 000 abdominal wall plastic surgeries performed every year worldwide. However, the most commonly used analgesic methods, such as oral administration, intravenous analgesia and local infiltration anesthesia, do not provide the satisfactory analgesic results. We found that intra-sheath injection of ropivacaine of the rectus abdomen was effective in reducing postoperative pain. Objectives To retrospectively study the analgesic effect of continuous pumping ropivacaine into the intra-sheath space of rectus abdominis after abdominoplasty. Methods A retrospective study was conducted on 67 patients with total abdominal wall plastic surgery admitted to Plastic Surgery Hospital of Chinese Academy of Medical Sciences from February 2020 to August 2021. The patients were from 25 to 56 years old, with a mean age of 38.5, ASA grade 1–2, BMI 27–33kg/m2, and rectus abdominis muscle separation range of 4–8cm. Based on the methods of postoperative analgesia, we divided patients into the following two groups: 29 patients in the conventional intravenous analgesic group (group A) and 38 patients in the rectus abdominis intrathecal analgesic group (group B). Group A received PCA with sufentanil 1.0μg/kg+ normal saline diluted to 100ml. Group B received continuous pumping of ropivacaine (0.2625%) through the rectus sheath internal tube in 100mL of normal saline and continued pumping at a rate of 2mL /h. Visual analog pain score (VAS score), analgesic pump pressure times and the degree of postoperative satisfaction were recorded at T1 (24h) and T2 (48h). The incidence of adverse drug reactions and complications related to nerve block within one week after operation were also recorded. Results The clinical data of patients with total abdominal wall plastic surgery in two groups were collected and analyzed. The patients in group B overall had lower postoperative VAS score, less analgesic pump usage, less nausea, vomiting, drowsiness and restlessness and a higher degree of postoperative satisfaction than those in group A. Conclusion Continuous pumping of ropivacaine through rectus sheath can effectively relieve postoperative pain, reduce postoperative adverse reactions and improve postoperative satisfaction. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online instructions to Authors www.springer.com/00266. Body Contouring LOE IV